Good News | Azvudine Won the First Prize of Henan Provincial Technical Invention Award

Recently, the People's Government of Henan Province released the Decisions on Science and Technology Awards of Henan Province. The project "Development and Application of Azvudine for the Treatment of COVID-19" won the first prize of Henan Provincial Technical Invention Award.

The Henan Provincial Science and Technology Awards are the highest awards for scientific and technological achievements in the province, which are established by the People's Government of Henan Province and granted once a year. By referring to the system of calibration review by grade adopted by the National Science and Technology Awards, Henan Province establishes its own calibration review mechanism for nomination, independent evaluation and voting by grade with the actual situation of the province being taken into consideration. Specifically, the Technical Invention Award focuses on the originality, advancement and technical value of the candidates. This year it was granted to a total of 16 projects, and the project "Development and Application of Azvudine for the Treatment of COVID-19" won the first prize for its originality and social value.

As the first approved Chinese oral drug for COVID-19, Azvudine Tablets has been included in the Diagnosis and Treatment Guideline for COVID-19 (9th Edition) and the Diagnosis and Treatment Guideline for COVID-19 (Tentative 10th Edition), and officially included in the national reimbursement drug list. In Jan. 2023, 34 experts in infection, respiration, critical care, and pharmacy were convened by the National Center for Infectious Diseases to publish the Expert Consensus on Antiviral Treatment for COVID Patients, and Azvudine Tablets was highly recognized by them. At present, Azvudine Tablets has cured countless patients infected with COVID-19, and continues to provide strong support for the scientific prevention and control of the pandemic and safeguard the people’s health, and contributes China's strength to a rapid global victory over the pandemic.

This award highly recognizes the originality and social value of Azvudine Tablets and affirms the capacity of Genuine Biotech for innovation, which will further inspire the company to step up its efforts in innovation. Over the past 11 years’ development, Genuine Biotech has insisted on innovation-driven business development, and has been committed to improving human health through genuine innovation. By focusing on the R&D of innovative drugs in the fields of viral diseases, tumors, and cerebrovascular diseases, the company has various best-in-class and first-in-class candidates. In the future, Genuine Biotech will be based in China, orientate the world, recruit global talents, strive to address unmet clinical needs with novel and better treatment options, and become a globally competitive biopharmaceutical company.